T1	Spec 455 461	assess
T2	SNP 483 514	single-nucleotide polymorphisms
T3	SNP 516 520	SNPs
R1	Equiv Arg1:T3 Arg2:T2	
T4	Entity 534 537	MHT
T5	Entity 130 156	menopausal hormone therapy
R2	Equiv Arg1:T4 Arg2:T5	
R3	Risk_Factor Arg1:T3 Arg2:T4	
T6	Association 545 549	risk
E1	Association:T6 bc:T8 bc2:T7
R4	Speculation_marker Arg1:E1 Arg2:T1	
T7	Cancer 565 575	lobular BC
A1	Cancer_Type T7 Other
T8	Cancer 553 560;573 575	overall BC
A2	Cancer_Type T8 Other
T10	Cancer 199 212	breast cancer
T11	Cancer 573 575	BC
T12	Entity 118 123	Women
R5	Population_assignment Arg1:T2 Arg2:T12	
R6	Equiv Arg1:T11 Arg2:T10	
T13	Entity 1102 1117	current MHT use
T14	Cancer 1129 1131	BC
T15	SNP 1140 1148	two SNPs
T16	Entity 1152 1157	chr13
R7	SNP_location Arg1:T15 Arg2:T16	
T17	Entity 1158 1167	near POMP
R8	SNP_location Arg1:T15 Arg2:T17	
R9	Risk_Factor Arg1:T15 Arg2:T13	
T18	Therapeutic_response 1079 1098	effect modification
E3	Therapeutic_response:T18 Theme:T14 Agent:T15 Agent2:T20 Agent3:T21
T19	Entity 1210 1218	SLC25A21
T20	SNP 1198 1206	two SNPs
R10	SNP_coupled_gene Arg1:T20 Arg2:T19	
T21	SNP 1253 1263	three SNPs
T22	Entity 1267 1272	PLCG2
R11	SNP_coupled_gene Arg1:T21 Arg2:T22	
R12	Risk_Factor Arg1:T20 Arg2:T13	
R13	Risk_Factor Arg1:T21 Arg2:T13	
T23	SNP 1375 1378	SNP
T24	Entity 1382 1388	TMEFF2
R14	Risk_Factor Arg1:T23 Arg2:T24	
T25	Cancer 1327 1337	lobular BC
A3	Cancer_Type T25 Other
T26	Therapeutic_response 1307 1318	association
E4	Therapeutic_response:T26 Theme:T25 Agent:T23 Agent2:T27 Agent3:T29 Agent4:T32
T27	SNP 1419 1426	one SNP
T28	Entity 1430 1434	CD80
R15	SNP_coupled_gene Arg1:T27 Arg2:T28	
T29	SNP 1465 1475	three SNPs
T30	Entity 1479 1484	chr17
T31	Entity 1485 1498	near TMEM132E
R16	SNP_location Arg1:T29 Arg2:T30	
R17	SNP_location Arg1:T29 Arg2:T31	
T32	SNP 1531 1539	two SNPs
T33	Entity 1543 1548	chr18
R18	SNP_location Arg1:T32 Arg2:T33	
T34	Entity 1549 1562	near SLC25A52
R19	SNP_location Arg1:T32 Arg2:T34	
T35	Spec 1347 1367	potentially modified
R20	Speculation_marker Arg1:E4 Arg2:T35	
T36	SNP 1608 1621	polymorphisms
T37	Entity 1625 1630;1642 1679	genes solute transportation in mitochondria
T38	Entity 1625 1630;1681 1704	genes transmembrane signaling
T39	Entity 1625 1630;1710 1732	genes immune cell activation
T40	Spec 1737 1758	potentially modifying
T41	Cancer 1759 1761	BC
T42	Therapeutic_response 1762 1766	risk
E5	Therapeutic_response:T42 Theme:T41 Agent:T36
R21	Speculation_marker Arg1:E5 Arg2:T40	
T43	Entity 1783 1801	current use of MHT
R22	Risk_Factor Arg1:T36 Arg2:T43	
R23	SNP_coupled_gene Arg1:T36 Arg2:T39	
R24	SNP_coupled_gene Arg1:T36 Arg2:T38	
R25	SNP_coupled_gene Arg1:T36 Arg2:T37	
T9	SNP 0 17	Genetic modifiers
T44	Entity 21 59	menopausal hormone replacement therapy
R26	Risk_Factor Arg1:T9 Arg2:T44	
T45	Cancer 64 77	breast cancer
T46	Association 78 82	risk
E2	Association:T46 bc:T45 snp_int:T9
T47	Therapeutic_response 8 17	modifiers
E6	Therapeutic_response:T47 Agent:T9 Theme:T45
